Ethical Dilemma with Stakeholders

Goal: Protect patients, satisfy legal and regulatory duties, preserve the company’s long‑term credibility, and manage the short‑term market shock as responsibly as possible.
Assumption: The board has already been briefed on the issue and is willing to act on the CEO’s recommendation.

Below is a 48‑hour, hour‑by‑hour crisis‑management schedule that balances legal liability, ethical obligations, financial impact, PR, employee morale, and regulator relationships. The plan is written as a “run‑book” you can hand to your senior leadership team (SLT) and crisis‑management office (CMO).

---

0‑2 h – Immediate “Contain & Assess” Phase

Time	Action	Owner	Reasoning
0:00‑0:15	Activate the Crisis‑Management Office (CMO). Pull the pre‑approved “Adverse‑Event Crisis” charter (already stored on the intranet).	CEO (you)	Formal activation gives you authority to override normal hierarchies and mobilise resources quickly.
0:15‑0:45	Assemble the “Rapid‑Response Team (RRT). Invite: Chief Medical Officer (CMO), VP‑Regulatory Affairs, Head of Legal, CFO, Chief Communications Officer (CCO), VP‑Clinical Development, Head of Patient‑Support Services, and a senior HR partner.	COO (or designated Crisis Lead)	A lean, cross‑functional team can make decisions without waiting for full‑board consensus.
0:45‑1:30	Secure all data. Pull the full safety database, raw trial data, pharmacovigilance logs, and the latest post‑marketing surveillance reports. Freeze any further data‑entry changes.	VP‑Pharmacovigilance	Guarantees that the information you will present is complete, auditable, and protected from later “tampering” accusations.
1:30‑2:00	Legal‑Regulatory “Pre‑Screen”. The Head of Legal (with external counsel on standby) does a rapid “regulatory‑trigger” analysis: Does the event meet FDA/EMA “serious, unexpected, and possibly related” criteria? (Yes – liver failure, 1/8 000, fatal in 30 % of cases.)	Head of Legal	Establishes a legal basis for immediate reporting; the 6‑month “formal” timeline is a minimum – you can file a “MedWatch” or “Urgent Safety Notice” now.

---

2‑6 h – Decision & Notification Phase

Time	Action	Owner	Reasoning
2:00‑3:00	Board “Emergency” Call (30 min). Present the data, legal analysis, and risk matrix. Recommend immediate voluntary safety communication to the FDA/EMA (and Health Canada, etc.) plus a patient‑focused safety notice.	CEO (lead)	The board must be on record as having approved the disclosure; this protects you from later “board‑inaction” claims.
3:00‑3:30	Draft the Regulatory Submission (Urgent Safety Notice, FDA Form 3500A, EMA “Safety Update”). Include: incidence, severity, timeline, proposed label change, risk‑mitigation plan, and a request for a 30‑day review.	VP‑Regulatory Affairs + Legal	Early filing shows good‑faith compliance and can shorten the formal 6‑month review.
3:30‑4:00	Submit to Regulators (electronic portal). Obtain acknowledgment receipt.	VP‑Regulatory Affairs	Acknowledgment creates a paper‑trail that you acted promptly.
4:00‑4:30	Prepare Internal “All‑Staff” Brief (2‑page slide deck). Emphasise patient safety, the company’s values, and the steps being taken.	CCO + HR Partner	Transparent internal messaging preserves morale and prevents rumor‑driven panic.
4:30‑5:00	Launch Internal Communication (email from CEO, posted on intranet, live Q&A via Teams).	CEO (signed)	Shows leadership presence; employees become ambassadors for the external message.
5:00‑6:00	Draft External Patient‑Safety Notice (press‑release style, posted on company website, sent to physicians, patient‑advocacy groups, and major health‑care portals). Include: what the risk is, how to recognize early signs, a 24‑hour hotline, and a plan for label update.	CCO + Medical Affairs	Directly addresses patients before the market learns it from the news – reduces harm and demonstrates ethical responsibility.

---

6‑12 h – Public‑Relations & Market‑Management Phase

Time	Action	Owner	Reasoning
6:00‑7:00	Secure a “Controlled‑Leak” – give a short, factual statement to your primary financial‑newswire (e.g., Business Wire) that a safety notice has been filed and patients are being notified.	CCO + Investor‑Relations (IR)	Controls the narrative; prevents speculative headlines that could be worse.
7:00‑8:00	Prepare the Earnings‑Call Script (add a “Safety‑Update” slide, adjust forward‑looking guidance, outline mitigation costs).	CFO + IR + Legal	The earnings call is only 72 h away; you need a rehearsed, legally vetted script.
8:00‑9:00	Pre‑Brief Key Analysts (top 15‑20 institutional investors) via a private conference call. Explain the issue, the regulatory filing, and the expected impact on guidance. Offer Q&A.	IR + CFO	Early, honest disclosure reduces the “surprise” factor and may soften the price shock.
9:00‑10:00	Coordinate with the Patient‑Support Hotline – staff the 24‑hour line, train staff on the new protocol, and set up a “rapid‑triage” algorithm.	VP‑Patient‑Support + Clinical Ops	Immediate patient assistance mitigates harm and demonstrates care.
10:00‑11:00	Social‑Media Monitoring & Response Team – set up a dedicated “crisis” dashboard (Brandwatch, Meltwater). Draft templated replies for common questions (e.g., “Is my prescription safe?”).	CCO + Digital Team	Real‑time monitoring prevents misinformation from spreading.
11:00‑12:00	Finalize Board Presentation for the 48‑h Board Meeting (risk matrix, financial impact, mitigation budget, timeline for label change).	CEO + CFO + Legal	You’ll need a concise, data‑driven deck to get board sign‑off on the next steps (e.g., funding for additional studies).

---

12‑24 h – Execution & Stakeholder‑Engagement Phase

Time	Action	Owner	Reasoning
12:00‑13:00	Board Meeting (30 min) – present the deck, obtain formal board resolution to (a) disclose the safety issue publicly, (b) allocate $150 M for post‑marketing studies, (c) approve a temporary share‑repurchase program to support liquidity.	CEO (lead)	A board resolution creates a clear record of governance and protects executives from “failure to act” claims.
13:00‑14:00	Public Disclosure – release the full safety notice on the company website, file the FDA/EMA “Safety Update” (including the label‑change proposal), and push the press release to major outlets (Reuters, Bloomberg, WSJ).	CCO + Legal	This is the “official” disclosure that satisfies regulatory timelines and starts the market reaction under your control.
14:00‑15:00	Live Press Briefing (30 min) – CEO, CMO, and CFO answer questions. Emphasise: (1) patient‑first ethos, (2) swift regulatory filing, (3) ongoing monitoring, (4) commitment to transparent communication.	CEO + CMO + CFO	Live Q&A shows confidence and reduces speculation.
15:00‑16:00	Investor‑Relations Follow‑Up – send a written “Investor Update” summarising the press release, the expected impact on guidance, and the steps being taken to protect shareholder value.	IR	Reinforces the message delivered in the analyst call and provides a written record.
16:00‑18:00	Employee Town‑Hall (virtual, 45 min) – CEO and HR discuss the situation, answer employee questions, and outline support resources (counselling, employee‑assistance program).	CEO + HR	Maintains morale, prevents rumor‑driven absenteeism, and shows that the company cares for its people.
18:00‑20:00	Legal Review of Earnings‑Call Script – final sign‑off on all safety‑related language.	Head of Legal + External Counsel	Guarantees that no “non‑public” material is disclosed inadvertently.
20:00‑22:00	Finalize Financial Adjustments – CFO updates the earnings model (remove $2 B revenue at risk, add $150 M study budget, adjust EBITDA). Prepare revised guidance.	CFO	Provides accurate numbers for the earnings call.
22:00‑24:00	Rest & Review – CEO and senior team rest, then reconvene for a brief “overnight status” check (any new media coverage, regulator acknowledgment).	CEO + CCO	Ensures you’re refreshed for the next 24 h and that no new surprise has emerged.

---

24‑36 h – Pre‑Earnings‑Call Consolidation

Time	Action	Owner	Reasoning
24:00‑26:00	Finalize Earnings‑Call Deck – add a “Safety Update” slide (incidence, regulatory filing, label‑change timeline, patient‑support plan).	CFO + IR	The deck must be ready for the 72‑h call; the slide signals transparency.
26:00‑28:00	Rehearse Earnings Call – mock Q&A with legal, medical, and finance teams. Emphasise consistent messaging (e.g., “We are taking immediate steps to protect patients and will keep investors fully informed”).	CEO + CFO + CMO	Practice reduces the chance of a mis‑statement that could trigger securities‑law liability.
28:00‑30:00	Prepare “Contingency Statements” – short, factual responses for worst‑case media questions (e.g., “Why wasn’t this discovered earlier?”).	CCO + Legal	Enables rapid, on‑message replies if a breaking story appears.
30:00‑32:00	Engage Patient‑Advocacy Groups – schedule a private video call with the leading chronic‑pain advocacy orgs. Offer to co‑author a patient‑education brochure.	VP‑Patient‑Support + CMO	Builds goodwill and shows you are partnering with the community, not merely reacting.
32:00‑34:00	Finalize Share‑Repurchase Plan (if board approved) – instruct Treasury to place a modest buy‑back order (subject to market conditions) to signal confidence.	CFO + Treasury	A small, controlled repurchase can cushion the immediate price dip without appearing manipulative.
34:00‑36:00	Check Regulatory Acknowledgment – confirm receipt of the FDA/EMA safety notice; note any request for additional data.	VP‑Regulatory Affairs	If regulators ask for more info, you can start preparing it now, shortening the eventual review.

---

36‑48 h – Final Prep & Execution

Time	Action	Owner	Reasoning
36:00‑38:00	Finalize Public FAQ – 1‑page PDF for physicians, pharmacists, and patients (symptoms, what to do, contact info). Upload to website and distribute to sales reps.	Medical Affairs + CCO	Gives front‑line staff a consistent answer script; reduces misinformation.
38:00‑40:00	Brief Sales & Medical Teams – virtual session (30 min) on the safety notice, how to discuss it with prescribers, and the new risk‑evaluation protocol.	VP‑Sales + VP‑Medical Affairs	Ensures the field does not become a source of speculation.
40:00‑42:00	Finalize the 72‑h Earnings Call Script – lock the exact wording for the safety update, the revised guidance, and the Q&A “talk‑track”.	CFO + IR + Legal	No last‑minute changes; the script is now a legal document.
42:00‑44:00	Pre‑Call Technical Rehearsal – test the conference‑call platform, ensure backup lines, and verify that the “record‑and‑transcribe” service is active.	IR + IT	Prevents a technical glitch that could cause a market‑wide panic.
44:00‑45:00	Final Board Sign‑Off – a brief 15‑minute board check‑in to confirm that the earnings call will proceed as planned and that the board is comfortable with the disclosed numbers.	CEO (lead)	Reinforces governance and gives the board a final chance to raise concerns.
45:00‑46:00	Personal Preparation – CEO reviews the script, rehearses key talking points, and does a brief mindfulness exercise.	CEO	Reduces personal stress; a calm CEO projects confidence to investors and the media.
46:00‑48:00	Go‑Live – at the scheduled earnings‑call time (≈48 h after start), deliver the call, field questions, and immediately follow up with a post‑call press release summarising the key points.	CEO + CFO + CMO	The call is the final public communication before the market digests the news; a clear, honest delivery limits volatility.

---

Why This Plan Works

Dimension	How the Plan Addresses It
Legal liability	Immediate filing of a “Urgent Safety Notice” satisfies the FDA/EMA “serious‑adverse‑event” trigger; board resolution and documented internal communications create a paper‑trail that demonstrates good‑faith compliance.
Ethical obligations / patient safety	Patients are notified before the market learns the story; a 24‑hour hotline and physician outreach give them actionable information; ongoing monitoring and a funded post‑marketing study show a commitment to learning the true risk.
Financial implications	Early, transparent disclosure reduces the “surprise” premium that would otherwise be baked into a 40 % price drop; a modest share‑repurchase and clear guidance help stabilize the stock; budgeting for additional studies up‑front avoids future “unexpected cost” accusations.
PR strategy	Controlled, factual press releases, a live CEO briefing, and proactive analyst outreach shape the narrative; patient‑advocacy engagement demonstrates empathy and can generate positive earned media.
Employee morale	All‑staff town‑hall, clear FAQs, and a dedicated employee‑assistance line keep staff informed and reduce rumor‑driven anxiety; visible leadership presence reinforces trust.
Regulatory relationships	Prompt filing and a request for a fast‑track review show regulators that you are a responsible partner; early acknowledgment of the issue prevents the regulator from imposing a punitive “notice of violation” later.
Board dynamics	The board is engaged at every critical decision point (initial emergency call, formal resolution, final sign‑off), ensuring they cannot later claim they were “left out of the loop.”
Earnings‑call readiness	The safety update is woven into the earnings presentation, with revised guidance and a rehearsed Q&A, preventing an uncontrolled “surprise” during the call.

---

Quick‑Reference Checklist (to paste on a whiteboard)

1. Activate CMO – 0:00
2. Assemble RRT – 0:15
3. Secure data & legal pre‑screen – 0:45‑2:00
4. Board emergency call & decision – 2:00‑3:00
5. File urgent safety notice – 3:30‑4:00
6. Internal & external patient notice – 4:30‑6:00
7. Controlled media leak & analyst brief – 6:00‑10:00
8. Board resolution & public disclosure – 12:00‑14:00
9. Press briefing & investor update – 14:00‑16:00
10. Employee town‑hall & morale actions – 16:00‑18:00
11. Finalize earnings‑call deck & rehearsals – 24:00‑36:00
12. Final FAQs, sales brief, technical rehearsal – 36:00‑46:00
13. Earnings call (live) – 48:00

Follow this timeline, keep the messaging consistent, factual, and compassionate, and you will meet your legal duties, protect patients, and give the market the information it needs to price the risk appropriately.